N-palmitoyl serinol pharmaceutical composition for cognitive impairment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative brain diseases such as autism, Alzheimer's, and Parkinson's lack effective solutions for improving cognitive ability and memory, with existing medications causing side effects and limited efficacy.

Innovation Solution

A pharmaceutical composition incorporating N-palmitoyl serinol (Neuromide) as a CB1 agonist, combined with active materials like Donepezil, is formulated for oral or parenteral administration, forming a stable crystal lamella micro-encapsulation system to enhance ceramide synthesis and acetylcholine levels, reducing inflammatory cytokines and improving cognitive function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing medications are used to treat neurodegenerative brain diseases, then cognitive function may be partially improved, but side effects occur and efficacy is limited

Engineering Contradiction:

ImproveefficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent combines N-palmitoyl serinol with other active materials (such as donepezil, galantamine, or rivastigmine) to create a composite pharmaceutical composition. This composite approach leverages the ceramide synthesis promotion effect of N-palmitoyl serinol alongside the acetylcholinesterase inhibition effects of other materials, achieving synergistic improvement in cognitive function while reducing reliance on high doses of single agents that cause side effects

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent changes the therapeutic parameter by introducing N-palmitoyl serinol which acts through a different mechanism (ceramide metabolism and SPT activation) compared to conventional acetylcholinesterase inhibitors. This parameter change provides an alternative pathway for cognitive improvement that does not rely solely on acetylcholine accumulation, thereby reducing side effects associated with conventional treatments

Inventive Principle:

Principle #35Parameter changes

2Reliability

If N-palmitoyl serinol is used to promote ceramide synthesis, then cognitive ability improves, but formulation stability must be maintained

Engineering Contradiction:

Improvecognitive improvement effectVSAvoidformulation stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent employs microencapsulation technology with shell materials (such as gelatin, chitosan, or polylactic-co-glycolic acid) to create flexible protective shells around N-palmitoyl serinol particles. These shells protect the active material from degradation while controlling its release, maintaining both formulation stability and cognitive improvement effects

Inventive Principle:

Principle #30Flexible shells and thin films

Solution Approach 2:

The patent uses nested structures where N-palmitoyl serinol is encapsulated within inner cores, which are then surrounded by intermediate layers, and finally outer protective shells. This multi-layer nesting provides progressive protection and controlled release, ensuring formulation stability while maintaining therapeutic efficacy

Inventive Principle:

Principle #7Nested doll (Nesting)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition significantly improves cognitive impairment and memory loss in neurodegenerative diseases by promoting ceramide synthesis, increasing acetylcholine, and decreasing inflammatory cytokines, offering a more effective and safer alternative to existing treatments.

Implementation Method 1

N-palmitoyl serinol (trade name: Neuromide) which is the effective component of the pharmaceutical composition for improving cognitive ability or enhancing memory of the present invention, has been confirmed to have an effect of significantly improving cognitive impairment or memory loss caused by a neurodegenerative brain disease or an inflammatory brain disease

Methodology Applied

Scientific EffectCB1 agonist mechanism:

Implementation Method 2

it has been confirmed that... decreased activity of acetylcholinesterase which is an acetylcholine decomposition enzyme, an increased amount of acetylcholine

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 3

a decrease in TNF-α and Il-1β which are inflammatory cytokines in various indicators of brain function

Methodology Applied

Scientific EffectAnti-inflammatory effect:

Data Source

PatentUS20240024261A1Pharmaceutical composition for improving cognitive ability or enhancing memory

Publication Date: 2024.01.25 DR RAYMOND LAB INC

AI summary

The present invention relates to a pharmaceutical composition for improving cognitive ability or enhancing memory, and more specifically, to a health functional food for improving cognitive ability or enhancing memory, and a composite pharmaceutical composition for improving cognitive ability or enhancing memory, which are mixed compositions, respectively, for co-administration with other active materials exhibiting an effect of improving cognitive ability or enhancing memory. The pharmaceutical composition for improving cognitive ability or enhancing memory, according to the present invention, has been confirmed to exhibit an effect of significantly reducing cognitive impairment or memory loss caused by neurodegenerative brain diseases or inflammatory brain diseases such as autism, Alzheimer's disease, Parkinson's disease, peripheral neuropathy, amyotrophic lateral sclerosis, ischaemia, stroke and multiple sclerosis, etc.